Zelicapavir demonstrates antiviral effect in phase 2 RSV study
Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.
What's going on with polio, monkeypox, and COVID-19
The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?
No unexpected reactions present among mRNA COVID-19 vaccination in kids
The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).
What Omicron could mean for the pandemic
Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.
Antiviral treatment for hospitalized influenza pediatric patients declining
From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.
COVID-19 among adolescents, teens and type 2 diabetes incidence
A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.
